We can support our patients with diabetic retinopathy throughout their treatment with Noctura 400 – remotely! Recently published in the Journal of Optometry and Ophthalmology, we highlight the need for effective home treatments. During severe hospital clinic disruption in the COVID-19 pandemic, Noctura 400 treatment was able to continue, unlike many other clinic-based treatments.

Read the full article here!

Summary: The objective of this study was to determine if patients with early diabetic macular oedema (DMO) would consistently use a sleep mask (Noctura 400) during sleep over a 2-year period with regular follow-up to monitor use. The study also evaluated the use of masks during the COVID-19 pandemic and the associated disruptions to hospital services. A total of 26 patients were recruited, and regular phone and text support was provided to help with mask use. In year 1, regular 3 monthly hospital visits were conducted, while in year 2, visits mostly did not take place due to COVID-19 restrictions, though phone calls and texts continued throughout the study period. At the end of year 1, the vast majority of patients found the mask comfortable and easy to use. Of the 26 patients, 21 completed the entire 2-year home treatment, with a high level of mask-wear compliance achieved (76.1% for the 2 years) when appropriately supported. Compliance dropped slightly (but not significantly) during the ongoing pandemic, with 85.7% of completing patients in the second year having no hospital visits. The study concluded that the Noctura 400 sleep mask was worn effectively for a prolonged period of time by the group of patients when appropriately supported, even during severe hospital service disruption. The study highlights the need for effective home treatments during unpredictable times.